| 000 | 01812 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514221344.0 | ||
| 264 | 0 | _c20050728 | |
| 008 | 200507s 0 0 eng d | ||
| 022 | _a0268-3369 | ||
| 024 | 7 |
_a10.1038/sj.bmt.1704871 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMamlouk, K | |
| 245 | 0 | 0 |
_aModification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cApr 2005 |
||
| 300 |
_a747-54 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aBusulfan _xadministration & dosage |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xprevention & control |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRadiometry |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTransplantation Conditioning |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSaracino, G | |
| 700 | 1 | _aBerryman, R B | |
| 700 | 1 | _aFay, J W | |
| 700 | 1 | _aPineiro, L A | |
| 700 | 1 | _aVance, E A | |
| 700 | 1 | _aWhite, M | |
| 700 | 1 | _aSandler, I | |
| 700 | 1 | _aAgura, E D | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 35 _gno. 8 _gp. 747-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bmt.1704871 _zAvailable from publisher's website |
| 999 |
_c15424209 _d15424209 |
||